Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 1
2024 pubmed 7 citations

STAT4 targets KISS1 to inhibit the oxidative damage, inflammation and neuronal apoptosis in experimental PD models by inactivating the MAPK pathway.

Zhang. XiaoLei X; Wang. Yu Y; Lv. Jia J

Key Findings

  • s‑like toxins, and boosting STAT4 reduces oxidative damage, inflammation, and neuron death.", "STAT4 directly suppresses the gene KISS1; raising KISS1 levels undoes STAT4
  • The protective effect of STAT4 involves shutting down the MAPK signaling pathway, which is re‑activated when KISS1 is increased.

Practical Outcomes

  • For DIY health enthusiasts, this research does not provide a clear, actionable way to use kisspeptin‑10 or related peptides for neuroprotection. It suggests that, at least in Parkinson's models, increasing KISS1 may be harmful, so any protocol that aims to boost kisspeptin should be approached with caution for brain health.

Summary

The study shows that a protein called STAT4 can protect brain cells from damage in a mouse model of Parkinson's disease, but it does this by turning off another protein called KISS1. When KISS1 is turned back on, the protection disappears, suggesting that KISS1 may actually worsen oxidative stress, inflammation, and cell death in the brain.

Abstract

Oxidative stress and neuroinflammation are proven to play critical roles in the pathogenesis of Parkinson's disease (PD). As reported, patients with PD have lower level of STAT4 compared with healthy subjects. However, the biological functions and mechanisms of STAT4 in PD pathogenesis remain uncertain. This study aimed to investigate the roles and related mechanisms of STAT4 in PD development. The intraperitoneal injection of MPTP (20&#xa0;mg/kg) dissolved in physiological saline was performed to mimic PD-like conditions in vivo. MPP&#xa0;<sup>+</sup>&#xa0;solution was prepared for cell model of PD. Cell viability was measured by CCK-8. Griess reaction was conducted to measure NO concentrations. The mRNA and protein levels were evaluated by RT-qPCR and western blotting. ROS generation was assessed by DCFH-DA. The levels of inflammatory cytokines were measured by ELISA. Cell apoptosis was examined by flow cytometry and western blotting. Moreover, the SH-SY5Y cells were treated with conditioned medium from LPS-stimulated microglia and subjected to CCK-8 assays and ELISA. Mechanistically, CHIP assays and luciferase reporter assays were performed to verify the binding relationship between KISS1 and STAT4. For in vivo analysis, the histological changes of midbrain tissues of mice were determined by hematoxylin and eosin staining. The expression of tyrosine hydroxylase (TH) was detected by immunohistochemistry staining. Iba-1 positive microglial cells in the striatum were assessed by immunofluorescence staining. For in vitro analysis, STAT4 level was downregulated after MPP<sup>+</sup> treatment, and STAT4 upregulation inhibited the oxidative damage, inflammation and apoptosis in SH-SY5Y cells. STAT4 bound at +215-228 region of KISS1, and KISS1 upregulation counteracted the protection of STAT4 upregulation against cell damage. Moreover, STAT4 upregulation inhibited cell viability loss and inflammation induced by conditioned medium from LPS-treated microglia, whereas KISS1 upregulation had the opposite effect. For in vivo analysis, the protective effects of STAT4 upregulation against inflammatory response, oxidative stress, dopaminergic neuronal loss and microglia activation were attenuated by KISS1 upregulation. Moreover, the inactivation of MAPK pathway caused by STAT4 upregulation was reversed by KISS1 upregulation, and MAPK inhibition attenuated the MPP<sup>+</sup>-induced inflammation, oxidative stress and apoptosis in SH-SY5Y cells. STAT4 inhibits KISS1 to attenuate the oxidative damage, inflammation and neuronal apoptosis in PD by inactivating the MAPK pathway.

Study Information

Provider

pubmed

Year

2024

Date

2024-02-08T00:00:00.000Z

DOI

10.1016/j.neuint.2024.105683

Citations

7

References

56